These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38228910)

  • 1. Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer.
    Li LB; Yang LX; Liu L; Liu FR; Li AH; Zhu YL; Wen H; Xue X; Tian ZX; Sun H; Li PC; Zhao XG
    Acta Pharmacol Sin; 2024 May; 45(5):1060-1076. PubMed ID: 38228910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition.
    Deng QD; Lei XP; Zhong YH; Chen MS; Ke YY; Li Z; Chen J; Huang LJ; Zhang Y; Liang L; Lin ZX; Liu Q; Li SP; Yu XY
    Acta Pharmacol Sin; 2021 Sep; 42(9):1486-1497. PubMed ID: 33893396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triptolide induces apoptosis through the calcium/calmodulin‑dependent protein kinase kinaseβ/AMP‑activated protein kinase signaling pathway in non‑small cell lung cancer cells.
    Ren T; Tang YJ; Wang MF; Wang HS; Liu Y; Qian X; Chang C; Chen MW
    Oncol Rep; 2020 Nov; 44(5):2288-2296. PubMed ID: 33000264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer.
    Reno TA; Tong SW; Wu J; Fidler JM; Nelson R; Kim JY; Raz DJ
    BMC Cancer; 2016 Jul; 16():439. PubMed ID: 27400883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes.
    Jiang N; Dong XP; Zhang SL; You QY; Jiang XT; Zhao XG
    Mol Med Rep; 2016 Jan; 13(1):153-9. PubMed ID: 26531258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Roles of Plant-Derived Triptolide on Non-Small Cell Lung Cancer.
    Wei J; Yan Y; Chen X; Qian L; Zeng S; Li Z; Dai S; Gong Z; Xu Z
    Oncol Res; 2019 Jul; 27(7):849-858. PubMed ID: 30982492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonist effect of triptolide on AKT activation by truncated retinoid X receptor-alpha.
    Lu N; Liu J; Liu J; Zhang C; Jiang F; Wu H; Chen L; Zeng W; Cao X; Yan T; Wang G; Zhou H; Lin B; Yan X; Zhang XK; Zeng JZ
    PLoS One; 2012; 7(4):e35722. PubMed ID: 22545132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and computational evaluation of Triptolide-induced cytotoxicity against NSCLC.
    Hamdi AM; Jiang ZZ; Guerram M; Yousef BA; Hassan HM; Ling JW; Zhang LY
    Biomed Pharmacother; 2018 Jul; 103():1557-1566. PubMed ID: 29864943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances on effects of triptolide with non-small cell lung cancer].
    Wang L; Song Y
    Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):378-81. PubMed ID: 23866670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity.
    Zhu J; Wang H; Chen F; Lv H; Xu Z; Fu J; Hou Y; Xu Y; Pi J
    Toxicol Appl Pharmacol; 2018 Nov; 358():1-9. PubMed ID: 30196066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
    Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
    EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITRAQ-Based Proteomics Analysis of Triptolide On Human A549 Lung Adenocarcinoma Cells.
    Li F; Zhao D; Yang S; Wang J; Liu Q; Jin X; Wang W
    Cell Physiol Biochem; 2018; 45(3):917-934. PubMed ID: 29428961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
    Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.
    Bacon NA; Larre I; Lawag AA; Merritt C; Smith M; Rosolen M; Sollars VE
    Biomed Pharmacother; 2020 Sep; 129():110434. PubMed ID: 32768937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptolide inhibits Wnt signaling in NSCLC through upregulation of multiple Wnt inhibitory factors via epigenetic modifications to Histone H3.
    Nardi I; Reno T; Yun X; Sztain T; Wang J; Dai H; Zheng L; Shen B; Kim J; Raz D
    Int J Cancer; 2018 Nov; 143(10):2470-2478. PubMed ID: 30006924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
    Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
    Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles.
    Liu J; Cheng H; Han L; Qiang Z; Zhang X; Gao W; Zhao K; Song Y
    Drug Des Devel Ther; 2018; 12():3199-3209. PubMed ID: 30288024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gli1 mediates lung cancer cell proliferation and Sonic Hedgehog-dependent mesenchymal cell activation.
    Bermudez O; Hennen E; Koch I; Lindner M; Eickelberg O
    PLoS One; 2013; 8(5):e63226. PubMed ID: 23667589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.